Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “buy” rating restated by equities research analysts at SunTrust Banks, Inc. in a note issued to investors on Friday. They currently have a $61.00 price target on the specialty pharmaceutical company’s stock. SunTrust Banks, Inc.’s price objective suggests a potential upside of 45.07% from the company’s previous close.
SUPN has been the topic of a number of other reports. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 target price on the stock. in a research note on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reiterated a “hold” rating and set a $45.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Cowen and Company reiterated a “positive” rating and set a $50.00 target price (up from $40.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 3rd. BidaskClub cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Janney Montgomery Scott reiterated a “hold” rating and set a $47.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $49.78.
Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $42.05 on Friday. The company has a quick ratio of 1.74, a current ratio of 1.94 and a debt-to-equity ratio of 0.01. The company has a market cap of $2,104.01, a price-to-earnings ratio of 36.40, a price-to-earnings-growth ratio of 1.81 and a beta of 1.30.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. equities analysts forecast that Supernus Pharmaceuticals will post 1.04 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “SunTrust Banks, Inc. Reaffirms “Buy” Rating for Supernus Pharmaceuticals, Inc. (SUPN)” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/04/suntrust-banks-inc-reaffirms-buy-rating-for-supernus-pharmaceuticals-inc-supn.html.
In related news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the completion of the sale, the vice president now owns 17,500 shares in the company, valued at $791,525. The disclosure for this sale can be found here. Insiders sold a total of 153,709 shares of company stock worth $7,223,108 over the last 90 days. 6.70% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Neumeier Poma Investment Counsel LLC raised its stake in Supernus Pharmaceuticals by 1.6% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock valued at $38,391,000 after acquiring an additional 14,430 shares during the period. Teachers Advisors LLC raised its stake in Supernus Pharmaceuticals by 6.9% in the 2nd quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock valued at $20,087,000 after acquiring an additional 29,939 shares during the period. Sheets Smith Wealth Management bought a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $378,000. Royce & Associates LP raised its stake in Supernus Pharmaceuticals by 22.3% in the 2nd quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock valued at $6,853,000 after acquiring an additional 29,000 shares during the period. Finally, Bank of America Corp DE grew its holdings in Supernus Pharmaceuticals by 10.7% during the 1st quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock valued at $11,361,000 after buying an additional 35,069 shares in the last quarter. Institutional investors and hedge funds own 95.06% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.